# Novo Nordisk A/S

Type: Company (NVO)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/novo-nordisk-as
Canonical HTML page: https://getbiobrief.com/entity/novo-nordisk-as

## Recent coverage (1 stories)

### Wegovy Pill at 267K Weekly Scripts, 90% of U.S. Oral Obesity Market—Novo Nordisk Q2
2026-08-10 22:51:34 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Novo Nordisk’s Q2 earnings reveal explosive uptake of its oral Wegovy pill, now commanding 90% of the U.S. oral obesity market with 267,000 weekly scripts. The therapy is expanding the GLP-1 market, with 80% of users being treatment-naïve, signaling a new era in obesity pharmacotherapy.
Full story: https://getbiobrief.com/story/novo-nordisk-q2-wegovy-pill-obesity-boom-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.